Please note that the ANZCTR website will be unavailable from 1pm until 2pm (AEST) on Wednesday 29th May for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00889382




Registration number
NCT00889382
Ethics application status
Date submitted
6/04/2009
Date registered
24/04/2009
Date last updated
22/09/2014

Titles & IDs
Public title
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Scientific title
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Secondary ID [1] 0 0
2009-010319-34
Secondary ID [2] 0 0
OSI-906-202
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Solid Tumors 0 0
Ovarian Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Ovarian and primary peritoneal

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - OSI-906
Treatment: Drugs - Paclitaxel

Experimental: Phase 1 Arm A - Intermittent OSI-906 Once Daily (QD) on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15 (except Treatment Period 1 (TP 1); in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22)

Experimental: Phase 1 Arm B1 - Continuous OSI-906 Twice Daily (BID) (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15;(except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15 and 22)

Experimental: Phase 1 Arm B2 - Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 (except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 5 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22); (additional PK sampling on Days 9 or 13 0r 14 for TP 1)

Experimental: Phase 1 Arm B3 - Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 with no separation in OSI-906 and paclitaxel dosing (except TP 1; in TP 1 continuous OSI-906 dosing 2 hours prior to the initiation of paclitaxel infusion on Day 8 only, with paclitaxel on Days 8, 15, and 22, and additional PK sampling on Day 9 or 13 or 14)

Experimental: Phase 2 Arm A - Intermittent OSI-906 QD on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15

Experimental: Phase 2 Arm B - Continuous OSI-906 BID from Day 1 onwards with paclitaxel on Days 1, 8, and 15

Experimental: Phase 2 Arm C - Paclitaxel on Days 1, 8, and 15

Experimental: Phase 2 Arm C Roll-over - Continuous OSI-906 BID from Day 1 onwards


Treatment: Drugs: OSI-906
Administered orally

Treatment: Drugs: Paclitaxel
Administered intravenously

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Determine Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) - Primary outcome measure for Phase 1 portion
Timepoint [1] 0 0
28 days
Primary outcome [2] 0 0
Progression Free Survival (PFS) - Primary outcome measure for the Phase 2 portion; The time from the date of randomization until date of radiographic disease progression per RECIST v1.1 or until death due to any cause
Timepoint [2] 0 0
36 months
Secondary outcome [1] 0 0
Objective Response Rate (ORR) - The proportion of patients with a confirmed response of Complete Response (CR) or Partial Response (PR) per RECEIST v1.1
Timepoint [1] 0 0
36 months
Secondary outcome [2] 0 0
Cancer Antigen 125 (CA125) Response Rate - Response Rate is defined as at least 50% reduction in serum CA-125 levels from pretreatment levels; Response rate is the proportion of patients with a CA-125 response among evaluable patients
Timepoint [2] 0 0
36 months
Secondary outcome [3] 0 0
Duration of Response (DOR) - The time from the date of the first documented radiographic response (CR/PR) to first documented radiographic progression or death due to underlying cancer
Timepoint [3] 0 0
36 months
Secondary outcome [4] 0 0
Duration of CA-125 Response (CA-125 DOR) - The time from the date of the first documented CA-125 response to the date of CA-125 progression
Timepoint [4] 0 0
36 months
Secondary outcome [5] 0 0
Overall Survival (OS) - The time from the date of randomization until the documented date of death
Timepoint [5] 0 0
36 months
Secondary outcome [6] 0 0
Safety assessed via physician exam, vital signs, clinical laboratory tests, electrocardiograms (ECG), and adverse events
Timepoint [6] 0 0
36 months

Eligibility
Key inclusion criteria
- Histologically or cytologically confirmed epithelial ovarian carcinoma Patients with
fallopian or peritoneal cancer will also be eligible

- Patients with any solid tumor that may be treated with weekly paclitaxel will be
eligible for the phase 1 portion

- For the phase 2 portion, patients must have elevated CA125 levels evaluable/assessable
according to Gynecological Cancer Intergroup (GCIG) criteria (ie, > 70 U/mL)
documented by 2 measurements at least 1 week apart

- Patients must have radiologically confirmed progressive disease by RECIST v1.1
criteria within 6 months prior to randomization. (patients must have measurable
disease according to RECIST v1.1)

- Eastern Cooperative Oncology Group (ECOG) performance status(PS) 0 -1

- Predicted life expectancy = 12 weeks

- Patients may have had prior therapy, providing the following conditions are met:

- Chemotherapy: Prior chemotherapy must have been completed at least 3 weeks prior
to study enrollment (6 weeks for mitomycin C, nitrosoureas or high-dose
carboplatin [= 600 mg/m²]and 4 weeks for investigational drugs

1. Patient should have recovered from any drug-related toxicities (with the
exception of grade 1 neuropathy and or alopecia)

2. Phase 1: While there is no limit on the number of prior regimens for
patients entered into the phase 1 portion, any prior taxane therapy must
have been administered on a 3 week schedule

3. Phase 2: Patients must have received prior chemotherapy, which must have
contained a platinum and a taxanes at some point. Any prior taxanes therapy
must have been administered on a 3 week schedule. A maximum of 2 prior
chemotherapy regimens are permitted. Patients must be refractory
radiologically confirmed by computerized tomography (CT) scan progressive
disease (PD) during chemotherapy) or resistant (radiologically confirmed by
CT scan PD within six months of completing chemotherapy) to their last
platinum-containing chemotherapy regimen

- Radiation: Patients may have had prior radiation therapy provided they have
recovered from the acute, toxic effects of radiotherapy prior to
registration/randomization. Radiated lesions cannot be chosen as the target
lesions

a. A minimum of 21 days must have elapsed between the end of radiotherapy and
registration/randomization into the study unless the radiation affected less than
25% of bone marrow

- Surgery: Previous surgery is permitted provided that adequate wound healing has
occurred prior to registration/randomization

- Fasting glucose = 150 mg/dL (8.3 mmol/L)

- Adequate hematopoietic, hepatic, and renal function defined as follows:

- Neutrophil count = 1.5 x 10 ^9 /L and platelet count > = 100 x 10^9/L;

- Bilirubin = 1.5 x Upper Limit of Normal (ULN);

- AST and/or ALT = 2.5 x ULN or < = 5 x ULN if patient has documented liver
metastases; and

- Serum creatinine = 1.5 x ULN

- Female patient must be either:

- Of non childbearing potential:

1. post-menopausal (defined as at least 1 year without any menses) prior to
Screening, or

2. documented surgically sterile or status post hysterectomy (at least 1 month
prior to Screening)

- Or, if of childbearing potential:

1. must have a negative urine pregnancy test at Screening, and

2. must use two forms of birth control (one of which must be a barrier method)
starting at Screening and throughout the study period and for 28 days [or 5
half lives, whichever is longer] after final study drug administration

- Female patient must not be breastfeeding at Screening or during the study period and
for 28 days [or 5 half lives of the study drug whichever is longer] after final study
drug administration

- Female patient must not donate ova starting at Screening and throughout the study
period and for 28 days [or 5 half lives of the study drug whichever is longer] after
final study drug administration

- Patients must provide verbal and written informed consent to participate in the study
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Diabetes mellitus currently requiring medication (eg, insulin or oral hypoglycemics)

- During the phase 2 portion, patients with histology of abdominal adenocarcinoma of
unknown origin or a diagnosis of a borderline ovarian tumor

- Previous or concurrent malignancies (excluding curatively treated basal or squamous
cell carcinoma of the skin or cervical carcinoma in situ) unless the patient has been
in remission for at least 3 years

- History of significant cardiovascular disease unless the disease is well-controlled.
Significant cardiac diseases includes second/third degree heart block; significant
ischemic heart disease; poorly controlled hypertension; congestive heart failure of
New York Heart Association (NYHA) Class II or worse (slight limitation of physical
activity; comfortable at rest, but ordinary physical activity results in fatigue,
palpitation, or dyspnea)

- History of cerebrovascular accident (CVA) within 6 months prior to
registration/randomization or that is not stable

- Prior therapy with an insulin-like growth factor (IGF-1R) inhibitor

- Use of drugs that have a risk of causing QT interval prolongation within 14 days prior
to Day 1 dosing

- Known or prior hypersensitivity to taxanes in spite of premedication or drugs
containing Cremophor

- Gastro-intestinal abnormalities, including bowel obstruction, inability to take oral
medication, requirement for intravenous (IV) alimentation,active peptic ulcer or prior
surgical procedures or bowel resection affecting absorption

- Active infection or serious underlying medical condition (including any type of active
seizure disorder within 12 months prior to registration/randomization) that would
impair the ability of the patient to receive protocol treatment

- History of any psychiatric condition that might impair the patient's ability to
understand or to comply with the requirements of the study or to provide informed
consent

- Pregnancy or breast-feeding

- Symptomatic brain metastases that are not stable, require steroids, are potentially
life threatening, or that have required radiation within 28 days prior to
registration/randomization

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to the study drug

- History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy,
trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is
symptomatic or requires treatment (= grade 3), left bundle branch block (LBBB), or
asymptomatic sustained ventricular tachycardia are not allowed. Patients with atrial
fibrillation controlled by medication are not excluded. Patients with mean QTcF
interval = 450 msec at screening are excluded

- Use of drugs that have a known risk of causing Torsade de Pointes (TdP) or that that
have a risk of causing QT interval prolongation within 14 days prior to Day 1 dosing
are prohibited

- Use of the potent CYP1A2 inhibitors ciprofloxacin and fluvoxamine. Other less potent
CYP1A2 inhibitors/inducers are not excluded

- Participated in any interventional clinical study or has been treated with any
investigational drugs within 30 days or 5 half lives whichever is longer, prior to the
initiation of Screening or during the course of the study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1/Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Recruitment hospital [1] 0 0
WestMead Hospital - WestMead
Recruitment hospital [2] 0 0
Mater Adult Hospital - South Brisbane
Recruitment hospital [3] 0 0
Royal Adelaide Hospital - North Terrace
Recruitment hospital [4] 0 0
Launceston General Hospital - Launceston
Recruitment hospital [5] 0 0
Frankston Hospital - Frankston
Recruitment hospital [6] 0 0
Border Medical Oncology - Wodonga
Recruitment hospital [7] 0 0
St. John of God Hospital, Bunbury - Bunbury
Recruitment hospital [8] 0 0
Sir Charles Gairdner Hospital - Perth
Recruitment hospital [9] 0 0
St. John of Gog Hospital, Subiaco - Subiaco
Recruitment postcode(s) [1] 0 0
2145 - WestMead
Recruitment postcode(s) [2] 0 0
4101 - South Brisbane
Recruitment postcode(s) [3] 0 0
5000 - North Terrace
Recruitment postcode(s) [4] 0 0
7250 - Launceston
Recruitment postcode(s) [5] 0 0
3199 - Frankston
Recruitment postcode(s) [6] 0 0
3690 - Wodonga
Recruitment postcode(s) [7] 0 0
6230 - Bunbury
Recruitment postcode(s) [8] 0 0
6009 - Perth
Recruitment postcode(s) [9] 0 0
6008 - Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Indiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Louisiana
Country [5] 0 0
United States of America
State/province [5] 0 0
New Jersey
Country [6] 0 0
United States of America
State/province [6] 0 0
North Carolina
Country [7] 0 0
United States of America
State/province [7] 0 0
Oklahoma
Country [8] 0 0
Canada
State/province [8] 0 0
Ontario
Country [9] 0 0
Canada
State/province [9] 0 0
Quebec
Country [10] 0 0
Czech Republic
State/province [10] 0 0
Kralove
Country [11] 0 0
Czech Republic
State/province [11] 0 0
Ostrava- Poruba
Country [12] 0 0
Czech Republic
State/province [12] 0 0
Prague
Country [13] 0 0
Italy
State/province [13] 0 0
Bologna
Country [14] 0 0
Italy
State/province [14] 0 0
Carpi
Country [15] 0 0
Italy
State/province [15] 0 0
Milan
Country [16] 0 0
Italy
State/province [16] 0 0
Roma
Country [17] 0 0
Poland
State/province [17] 0 0
Lublin
Country [18] 0 0
Poland
State/province [18] 0 0
Poznan
Country [19] 0 0
Romania
State/province [19] 0 0
Cluj Napoca
Country [20] 0 0
Romania
State/province [20] 0 0
Iasi
Country [21] 0 0
Romania
State/province [21] 0 0
Mures
Country [22] 0 0
Russian Federation
State/province [22] 0 0
Moscow
Country [23] 0 0
Russian Federation
State/province [23] 0 0
Obninsk
Country [24] 0 0
Russian Federation
State/province [24] 0 0
St. Petersburg
Country [25] 0 0
Switzerland
State/province [25] 0 0
Bellinzona
Country [26] 0 0
United Kingdom
State/province [26] 0 0
Surrey
Country [27] 0 0
United Kingdom
State/province [27] 0 0
London
Country [28] 0 0
United Kingdom
State/province [28] 0 0
Manchester
Country [29] 0 0
United Kingdom
State/province [29] 0 0
Northwood
Country [30] 0 0
United Kingdom
State/province [30] 0 0
Oxford
Country [31] 0 0
United Kingdom
State/province [31] 0 0
Withington

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Astellas Pharma Inc
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly
paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with
recurrent/relapsed ovarian and other solid tumors.
Trial website
https://clinicaltrials.gov/show/NCT00889382
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Astellas Pharma Global Development
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications